tetano
Editor, Senior Moderator
Front Microbiol
. 2022 Jun 9;13:922042.
doi: 10.3389/fmicb.2022.922042. eCollection 2022.
Long-Term Humoral Response After a Second Dose of SARS-CoV-2 mRNA Vaccine in Japanese Kidney Transplant Recipients
Yutaro Ohki[SUP] 1 [/SUP], Mayuko Kawabe[SUP] 1 [/SUP], Izumi Yamamoto[SUP] 1 [/SUP], Haruki Katsumata[SUP] 1 [/SUP], Yasuyuki Nakada[SUP] 1 [/SUP], Akimitsu Kobayashi[SUP] 1 [/SUP], Fumihiko Urabe[SUP] 2 [/SUP], Jun Miki[SUP] 2 [/SUP], Hiroki Yamada[SUP] 2 [/SUP], Takahiro Kimura[SUP] 2 [/SUP], Nanae Matsuo[SUP] 1 [/SUP], Yudo Tanno[SUP] 1 [/SUP], Tetsuya Horino[SUP] 3 [/SUP], Ichiro Ohkido[SUP] 1 [/SUP], Hiroyasu Yamamoto[SUP] 1 [/SUP], Takashi Yokoo[SUP] 1 [/SUP]
Affiliations
Abstract
Background: The mortality rate due to COVID-19 in kidney transplant recipients (KTRs) is 16.8 to 32%. Vaccination against COVID-19 is expected to contribute to the prevention of infection, severe disease, and mortality; however, it has been reported that the humoral response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine in KTRs is poor. Vaccination strategies against COVID-19 vary from country to country, and in Japan, the third dose is given 6 months after the second dose. Few studies have evaluated long-term humoral responses after the second dose of SARS-CoV-2 mRNA vaccine. In addition, the superiority of BNT162b2 vaccine and mRNA-1,273 vaccine in KTRs regarding humoral response is controversial.
Methods: Ninety-four KTRs were administered a second dose of the BNT162b2 or mRNA-1,273 vaccines, and anti-spike (anti-S) and anti-nucleocapsid (anti-N) SARS-CoV-2 antibody levels were measured 5 months (149.2 ± 45.5 days) later. The cutoff value of anti-S antibodies was defined ≥50 AU/ml and 1.4 Index for anti-N antibodies. The primary outcome was the rate of seropositivity, and factors associated with an appropriate humoral response were assessed by univariate and multivariate analysis.
Results: Of 94 KTRs, only 45 (47.9%) patients were positive for anti-S antibodies. The median anti-S SARS-CoV-2 IgG antibody titers was 35.3 (Interquartile range 3.8 to 159.7). Anti-N SARS-CoV-2 IgG antibodies in all patients were < 1.4 Index. Response to SARS-CoV-2 mRNA vaccines were 43.2 and 65% for BNT162b2 and mRNA-1,273, respectively (p = 0.152). In comparison with high-dose, low-dose of mycophenolic acid was a robust factor associated with an adequate humoral response.
Conclusion: The long-term humoral response after a second dose of SARS-CoV-2 mRNA vaccine in Japanese KTRs was poor. In comparison with high-dose, low-dose mycophenolic acid was related to an appropriate humoral response. Five months is too long to wait for a 3rd dose after 2nd dose of SARS-CoV-2 vaccine in KTRs. In this cohort, there was no statistical difference in humoral response to the BNT162b2 and mRNA-1,273 vaccines. Additional large observational studies and meta-analyses are needed to clarify the factors related to an appropriate humoral immune response to COVID-19 vaccination.
Keywords: COVID-19; SARS-CoV-2 vaccine; anti-S SARS-CoV-2 IgG antibody titers; humoral response; kidney transplant recipients.
. 2022 Jun 9;13:922042.
doi: 10.3389/fmicb.2022.922042. eCollection 2022.
Long-Term Humoral Response After a Second Dose of SARS-CoV-2 mRNA Vaccine in Japanese Kidney Transplant Recipients
Yutaro Ohki[SUP] 1 [/SUP], Mayuko Kawabe[SUP] 1 [/SUP], Izumi Yamamoto[SUP] 1 [/SUP], Haruki Katsumata[SUP] 1 [/SUP], Yasuyuki Nakada[SUP] 1 [/SUP], Akimitsu Kobayashi[SUP] 1 [/SUP], Fumihiko Urabe[SUP] 2 [/SUP], Jun Miki[SUP] 2 [/SUP], Hiroki Yamada[SUP] 2 [/SUP], Takahiro Kimura[SUP] 2 [/SUP], Nanae Matsuo[SUP] 1 [/SUP], Yudo Tanno[SUP] 1 [/SUP], Tetsuya Horino[SUP] 3 [/SUP], Ichiro Ohkido[SUP] 1 [/SUP], Hiroyasu Yamamoto[SUP] 1 [/SUP], Takashi Yokoo[SUP] 1 [/SUP]
Affiliations
- PMID: 35756063
- PMCID: PMC9218893
- DOI: 10.3389/fmicb.2022.922042
Abstract
Background: The mortality rate due to COVID-19 in kidney transplant recipients (KTRs) is 16.8 to 32%. Vaccination against COVID-19 is expected to contribute to the prevention of infection, severe disease, and mortality; however, it has been reported that the humoral response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine in KTRs is poor. Vaccination strategies against COVID-19 vary from country to country, and in Japan, the third dose is given 6 months after the second dose. Few studies have evaluated long-term humoral responses after the second dose of SARS-CoV-2 mRNA vaccine. In addition, the superiority of BNT162b2 vaccine and mRNA-1,273 vaccine in KTRs regarding humoral response is controversial.
Methods: Ninety-four KTRs were administered a second dose of the BNT162b2 or mRNA-1,273 vaccines, and anti-spike (anti-S) and anti-nucleocapsid (anti-N) SARS-CoV-2 antibody levels were measured 5 months (149.2 ± 45.5 days) later. The cutoff value of anti-S antibodies was defined ≥50 AU/ml and 1.4 Index for anti-N antibodies. The primary outcome was the rate of seropositivity, and factors associated with an appropriate humoral response were assessed by univariate and multivariate analysis.
Results: Of 94 KTRs, only 45 (47.9%) patients were positive for anti-S antibodies. The median anti-S SARS-CoV-2 IgG antibody titers was 35.3 (Interquartile range 3.8 to 159.7). Anti-N SARS-CoV-2 IgG antibodies in all patients were < 1.4 Index. Response to SARS-CoV-2 mRNA vaccines were 43.2 and 65% for BNT162b2 and mRNA-1,273, respectively (p = 0.152). In comparison with high-dose, low-dose of mycophenolic acid was a robust factor associated with an adequate humoral response.
Conclusion: The long-term humoral response after a second dose of SARS-CoV-2 mRNA vaccine in Japanese KTRs was poor. In comparison with high-dose, low-dose mycophenolic acid was related to an appropriate humoral response. Five months is too long to wait for a 3rd dose after 2nd dose of SARS-CoV-2 vaccine in KTRs. In this cohort, there was no statistical difference in humoral response to the BNT162b2 and mRNA-1,273 vaccines. Additional large observational studies and meta-analyses are needed to clarify the factors related to an appropriate humoral immune response to COVID-19 vaccination.
Keywords: COVID-19; SARS-CoV-2 vaccine; anti-S SARS-CoV-2 IgG antibody titers; humoral response; kidney transplant recipients.